Advancement in the 1L Treatment of Unresectable or Metastatic HCC: A Case-Based Review of the IMbrave150 Trial
Tuesday, 11 May 2021
7:00pm - 8:00pm EDT
The Society of Interventional Oncology (SIO) invites you to join us for an upcoming webinar, taking place Tuesday, 11 May at 6-7 p.m. EDT on the topic of Treatment and Management of HCC using the IMBrave 150 Regimen.
The HCC Branded Speaker program is a case-based branded speaker program designed to educate other HCPs about the treatment and management of HCC using the IMbrave150 regimen.
Case studies are used as a basis to address the following topics:
- Disease Overview and Staging
- IMbrave150 Clinical Trial
- Important Safety Information